- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Indian Pharma Market to Hit Rs 2.38 Lakh Crore by 2025: Pharmarack Report
New Delhi: The Indian Pharma Market (IPM) is set to grow by 8.2% in 2025, reaching Rs 2.38 lakh crore under a realistic scenario, according to the Market Growth Compass Report by Pharmarack.
This follows an 8% growth in 2024 and a five-year CAGR of 10.4%, driven primarily by price increases and new product launches.
As per the report, key drivers include evolving therapy behaviors post-COVID, normalization of disease patterns since 2022, and the increasing impact of innovative molecule launches and generics as patents expire. Policy interventions like the National List of Essential Medicines (NLEM) updates and bans on fixed-dose combinations (FDCs) further shape market dynamics.
Additionally, growing awareness of obesity treatments, a shift toward over-the-counter (OTC) products, and rising online sales significantly contribute to the changing market landscape.
Also Read: Indian Pharma Market Grows at 9.9 Percent, Vaccine Sales See Sharp Decline: Pharmatrac Report
Therapy-wise, cardiac and gastrointestinal segments are at the forefront of growth, with projected increases of 8.3% and 9.6%, respectively, in 2025. Other notable areas include respiratory therapies at 8.7% and anti-neoplastics at 9.8%. However, vaccines stand out as a declining category, expected to drop by 1.8% under the realistic scenario, highlighting segment-specific challenges.
Three scenarios—optimistic, realistic, and pessimistic—were explored to provide comprehensive insights. The optimistic scenario projects Rs. 239,893 crore (9% growth), driven by rapid adoption of new therapies, while the pessimistic scenario suggests Rs. 236,285 crore (7.4% growth), accounting for slower market adoption and other constraints.
Also Read: Indian Pharma Market Posts Robust 10.7 Percent Growth In November, Foracort Tops Sales: IQVIA
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751